Arca
Skip to content
Tools
Tools

Hypoxia-inducible factor prolyl hydroxylase

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2
  • Genes: 4

Who is on it, and how far along

Every drug ChEMBL records acting on EGLN1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Roxadustat
  • Daprodustat

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        RoxadustatApprovedKyntra BioSmall moleculeInhibitorHypoxia-inducible factor prolyl hydroxylase inhibitor11
        DaprodustatBoxed warningApprovedGSKSmall moleculeInhibitorHypoxia-inducible factor prolyl hydroxylase inhibitor3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
        Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass SurgeryRoxadustatPhase 4Not yet recruitingPeking University First HospitalNov 3, 2026
        Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing DialysisDaprodustatNot applicableNot yet recruitingServices Hospital, LahoreAug 10, 2026
        A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)RoxadustatPhase 3Not yet recruitingKyntra BioJul 23, 2026
        REDCURE Registry for Chronic Kidney Disease (CKD) AnemiaDaprodustat—Not yet recruitingNabiqasim Industries (Pvt) LtdJan 16, 2026
        A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)DaprodustatPhase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.Dec 23, 2025
        Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney DiseaseRoxadustat—Not yet recruitingZhongda HospitalDec 8, 2025
        Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis PatientsRoxadustatPhase 4Not yet recruitingTianjin Medical University General HospitalSep 9, 2025
        A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)RoxadustatNot applicableRecruitingGuangdong Provincial People's HospitalAug 22, 2025
        Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term DialysisRoxadustatPhase 4RecruitingChinese PLA General HospitalJul 1, 2025
        Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis PatientsRoxadustatPhase 1 / Phase 2RecruitingMansoura UniversityApr 9, 2025
        Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis PatientsRoxadustatPhase 1 / Phase 2RecruitingMansoura UniversityMar 30, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3831261, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.